The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Baseline characteristics associated with PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19).
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - Advanced Accelerator Applications; Alessa Therapeutics; Alessa Therapeutics; Amgen; AstraZeneca; Axiom Biotechnologies; Clovis Oncology; Dendreon; Jubilant Pharmaceuticals; Merck; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BioXCel therapeutics (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
 
Glenn Heller
No Relationships to Disclose
 
David W. Hillman
No Relationships to Disclose
 
Han Xiao
No Relationships to Disclose
 
Joel Picus
Consulting or Advisory Role - Pfizer
Research Funding - BioClin Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Mirati Therapeutics (Inst); Seagen (Inst); TRACON Pharma (Inst)
 
Mary-Ellen Taplin
Honoraria - Abbvie; Arcus Biosciences; Arvinas; AstraZeneca; Blue Earth Diagnostics; Clovis Oncology; Constellation Pharmaceuticals; Epizyme; Hengrui Therapeutics; Janssen-Ortho; Pfizer; Propella Therapeutics; Research to Practice; Roivant; Targeted Oncology; UpToDate
Consulting or Advisory Role - Arcus Ventures (I); AstraZeneca; Bayer; Best Doctors, Inc; Clovis Oncology; Janssen-Ortho; Myovant Sciences; Pfizer; Research to Practice; UpToDate
Research Funding - Janssen-Ortho (Inst)
Travel, Accommodations, Expenses - Advanced Prostate Cancer Society
 
Tanya B. Dorff
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Exelixis; Janssen Oncology; Pfizer; Seagen
Research Funding - Pfizer (Inst)
 
Leonard Joseph Appleman
Consulting or Advisory Role - AADi
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Epizyme (Inst); Exelixis (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Janssen Oncology; Lilly (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Surface Oncology (Inst)
Other Relationship - Pfizer
(OPTIONAL) Uncompensated Relationships - Exelixis
 
Douglas Jay Weckstein
No Relationships to Disclose
 
Akash Patnaik
Stock and Other Ownership Interests - Gilead Sciences; Infinity Pharmaceuticals; Merck; Merck
Honoraria - Medscape; Prime Oncology
Consulting or Advisory Role - Curio Science; Exelixis; Gerson Lehrman Group; Guidepoint Pharmacy
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Laekna Health Care (Inst); Progenics (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Exelixis; Prime Oncology
 
Alan Haruo Bryce
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; Castle Biosciences; Horizon CME; Myovant Sciences; Myovant Sciences; Pfizer; Research to Practice; Research to Practice; Verity Pharmaceuticals
Travel, Accommodations, Expenses - Clovis Oncology (Inst); Phosplatin Therapeutics (Inst)
 
Daniel H. Shevrin
Speakers' Bureau - Bayer; Sanofi/Aventis
 
James Mohler
Patents, Royalties, Other Intellectual Property - Mohler JL, Fiandalo M, Watt D, Sviripa V. Compounds and methods to impair androgen receptor (AR) activation, impair dimerization, and/or impair AR transregulation. Provisional patent application 62/839,676, filed 04/27/2019, by Health Research Inc. & Univ (Inst); Mohler JL, Fiandalo M, Watt D, Sviripa V. Coumarin-modified androgens for the treatment of prostate. cancer. International Patent Cooperation Treaty PCT/US2020/03014, filed 05/14/2020 by Health Research Inc. and Univ. of Kentucky Research Foundation (Inst); Mohler JL, Fiandalo M, Watt D, Sviripa V. Inhibitors of androgen receptor activation and methods of making and using same. Provisional patent application 62/890,292, filed 08/22/2019, by Health Research Inc. & Univ. of Kentucky Research Foundation (Inst); Mohler JL, Fiandalo M, Watt D, Sviripa V. Spirocyclic dihydrotestosterone as ligand for proteolysis chimeras for AR degradation, imaging agents, and screening tools for the treatment of prostate cancer. U.S. Provisional patent application 62/844,062, file (Inst)
 
Daniel M. Anderson
No Relationships to Disclose
 
Arpit Rao
Leadership - Ankr
Stock and Other Ownership Interests - AstraZeneca
Honoraria - Bayer; Bristol-Myers Squibb; Cardinal Health; Dendreon; Eisai; Lilly; Sanofi
Consulting or Advisory Role - Lilly (Inst)
Speakers' Bureau - Bristol Myers Squibb
Research Funding - Clovis Oncology (Inst); Lilly (Inst); Pfizer/Astellas (Inst); Seattle Genetics/Astellas (Inst)
 
Scott T. Tagawa
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Dendreon; Endocyte; Genentech; Genomic Health; Gilead Sciences; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
Alan Tan
Stock and Other Ownership Interests - Adaptimmune; Aprea AB; Bluebird Bio; crispr therapeutics; Editas Medicine; FATE Therapeutics; Geron; Iovance Biotherapeutics; Jounce Therapeutics; MEI Pharma; Myovant Sciences; Nektar; Sangamo Therapeutics
Honoraria - AstraZeneca; Bristol Myers Squibb Foundation; Verastem
Consulting or Advisory Role - Exelixis; Foundation Medicine
Speakers' Bureau - AstraZeneca; bristol myers squibb; verastem
 
Scott E. Eggener
Consulting or Advisory Role - Candel Therapeutics; Francis Medical; InSightec; Profound Medical
Speakers' Bureau - Janssen
(OPTIONAL) Uncompensated Relationships - Steba Biotech
 
Charles J. Ryan
Honoraria - Bayer; Janssen Oncology
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Clovis Oncology (Inst); Dendreon; Myovant Sciences; Roivant
Research Funding - Clovis Oncology (Inst); Genzyme (Inst)
 
Michael J. Morris
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Amgen; AstraZeneca; Clarity Pharmaceuticals; Convergent Therapeutics; Daiichi; Exelixis; ITM Isotope Technologies Munich; Lantheus Medical Imaging; NCCN; Pfizer
Research Funding - Bayer (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Janssen (Inst); Novartis (Inst); Progenics (Inst); Roche/Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - Bayer; Janssen Oncology; Novartis